Key Takeaways
The U.S. Supreme Court on May 18 rebuffed a pharmaceutical industry challenge to Medicare's authority to negotiate drug prices, upholding a key Biden administration policy. The justices declined to hear multiple challenges from drugmakers, leaving in place lower court rulings that affirmed the negotiation program established under the 2022 Inflation Reduction Act.
"Contrary to its statutory name, it involves no genuine 'negotiation,'" lawyers for AstraZeneca told the Supreme Court in their appeal, arguing the only alternative is to withdraw all drugs from Medicare and Medicaid, which would foreclose nearly half the U.S. prescription-drug market.
The first round of negotiations covering 10 drugs, including treatments for cancer, heart disease, and diabetes, produced an estimated $6 billion in annual Medicare savings. All 10 manufacturers accepted the negotiated prices, which resulted in price cuts ranging from 38 percent to 79 percent. Seniors with Medicare coverage began seeing lower out-of-pocket costs for these drugs in January.
The decision solidifies a program projected to save Medicare $12 billion annually by 2027. The next round of negotiations for 15 additional drugs, including the popular GLP-1 treatments Ozempic and Wegovy, is set to begin next year. Drugmakers had argued the program was unconstitutional, claiming it amounted to the government taking private property without fair compensation, a violation of the Fifth Amendment. However, lower courts ruled that because participation in the program is voluntary, the takings clause does not apply.
The ruling is a significant blow to the pharmaceutical lobby and confirms the legality of a policy aimed at lowering drug costs, potentially squeezing profit margins for drugmakers heavily reliant on Medicare. Investors will now be closely watching the upcoming negotiation rounds for 15 more drugs and any potential legislative responses from the industry.
This article is for informational purposes only and does not constitute investment advice.
